Veteran-owned business
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

For research use only. Not for human consumption.

Retatrutide (15mg/30mg/50mg)

Retatrutide is an investigational triple-agonist peptide that simultaneously targets GLP‑1, GIP, and glucagon receptors to promote weight loss, improved insulin sensitivity, and enhanced metabolic regulation in research and clinical studies.

Price:

Price range: $150.00 through $400.00

Select Quantity:

Overview

Retatrutide is a synthetic peptide designed as a triple-agonist, simultaneously activating three key hormone receptors: GLP‑1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor (GCGR). This multi-receptor approach allows Retatrutide to combine appetite suppression, improved insulin sensitivity, and increased energy expenditure, producing significant body weight reduction and metabolic improvements in preclinical and clinical research.

Unlike single or dual incretin therapies, Retatrutide’s triple-agonist design targets multiple metabolic pathways for a synergistic effect on obesity, type 2 diabetes, and cardiometabolic health. It is delivered via subcutaneous injection and is currently investigational, being evaluated in Phase III clinical trials.

Key Features

  • Type: Synthetic triple-agonist peptide

  • Receptors Targeted: GLP‑1R, GIPR, and GCGR

  • Mechanism of Action: Appetite suppression, enhanced insulin response, increased energy expenditure

  • Delivery: Once-weekly subcutaneous injection

  • Research Use: Preclinical and clinical studies in obesity, metabolic disorders, and type 2 diabetes

Summary

Retatrutide is a next-generation multi-receptor peptide that leverages GLP‑1, GIP, and glucagon signaling to produce weight loss and metabolic benefits. Its synergistic triple-agonist mechanism distinguishes it from older incretin-based therapies and makes it a focus of research into advanced obesity and metabolic treatments.

Biochemical
Characteristics

1️⃣ Molecular Structure

  • Type: Synthetic peptide

  • Amino Acid Length: Modified sequence derived from GLP‑1, GIP, and glucagon analogs

  • Molecular Weight: Approximately ~5000–6000 Da (varies slightly by formulation and modifications)

  • Structure: Linear peptide with chemical modifications to enhance stability, receptor specificity, and half-life

  • Receptor Targets: GLP‑1R, GIPR, and GCGR


2️⃣ Functional Biochemistry

  • Multi-Receptor Activation: Engages three hormone receptors simultaneously for synergistic metabolic effects

  • Appetite Regulation: Activates GLP‑1 and GIP pathways in the CNS and pancreas to reduce food intake

  • Energy Metabolism: Stimulates GCGR-mediated energy expenditure and fat oxidation

  • Insulin and Glucose Control: Enhances insulin secretion and glucose homeostasis through incretin pathways

  • Stability: Chemically modified to resist enzymatic degradation and prolong in vivo activity


3️⃣ Physiological Effects

  • Weight Management: Reduces body weight via appetite suppression and increased energy expenditure

  • Glycemic Control: Improves fasting glucose, insulin sensitivity, and HbA1c levels

  • Metabolic Health: Potentially improves lipid metabolism, cardiovascular markers, and overall metabolic profile


4️⃣ Peptide Properties

  • Water-Soluble: Suitable for in vitro and preclinical research

  • Modified Linear Peptide: Includes amino acid substitutions and chemical modifications for enhanced receptor affinity and pharmacokinetics

  • Half-Life: Optimized for once-weekly dosing in clinical trials


Summary

Retatrutide is a synthetic, multi-receptor peptide with biochemical properties tailored for simultaneous GLP‑1, GIP, and glucagon receptor activation. Its water solubility, chemical modifications, receptor specificity, and enzymatic stability make it ideal for research on obesity, metabolic disorders, and type 2 diabetes.

Research Applications

1️⃣ Obesity and Weight Management Studies

  • Investigating mechanisms of appetite suppression and satiety via GLP‑1 and GIP pathways

  • Studying energy expenditure and fat oxidation mediated by glucagon receptor activation

  • Researching synergistic effects of triple-agonist peptides on body weight reduction

  • Evaluating potential therapeutic strategies for severe obesity


2️⃣ Metabolic and Glycemic Regulation

  • Examining insulin secretion, glucose homeostasis, and HbA1c improvement

  • Researching effects on insulin sensitivity and pancreatic beta-cell function

  • Studying incretin-based mechanisms in type 2 diabetes models


3️⃣ Cardiometabolic Health

  • Investigating lipid metabolism and cardiovascular markers

  • Researching the impact of triple-receptor activation on overall metabolic profile

  • Studying mechanisms underlying metabolic syndrome and related disorders


4️⃣ Peptide Therapeutics and Drug Development

  • Exploring multi-receptor agonist peptide design and structure-activity relationships

  • Studying pharmacokinetics, receptor specificity, and chemical modifications to improve half-life and stability

  • Evaluating preclinical safety, efficacy, and translational potential


Summary

Retatrutide is used in research for obesity, metabolic disorders, type 2 diabetes, and cardiometabolic health, leveraging its triple-receptor mechanism (GLP‑1, GIP, glucagon) to study weight loss, glucose regulation, and metabolic improvements. Its stability, receptor specificity, and pharmacological profile make it a valuable tool in preclinical and clinical translational studies.

Chemical Properties
COA /HPLC / MS

 

3rd Party Testing
Storage

1️⃣ Lyophilized (Powder) Form

  • Temperature: Store refrigerated at 2–8 °C (36–46 °F) for short-term use

  • Long-Term Storage: Freeze at −20 °C or lower for extended stability

  • Light Protection: Keep protected from direct light

  • Moisture Protection: Store in tightly sealed, dry vials

  • Shelf Life: Typically 12–24 months under proper storage conditions


2️⃣ Reconstituted Solution

  • Diluent: Sterile water or appropriate buffer

  • Temperature: Store refrigerated at 2–8 °C

  • Use Period: Recommended within 7–14 days after reconstitution

  • Handling: Gently swirl to dissolve; avoid vigorous shaking

  • Do NOT freeze after reconstitution


3️⃣ General Precautions

  • Inspect solution before use: should be clear, colorless, and free of particulates

  • Discard if cloudy, discolored, or precipitated

  • Use sterile techniques during reconstitution and experimental handling

  • Protect from heat, light, and mechanical agitation to preserve peptide integrity


Summary

Retatrutide is most stable as a lyophilized powder stored refrigerated or frozen. Once reconstituted, it should be kept cold, protected from light, and used promptly to maintain biological activity for research in obesity, metabolic disorders, and type 2 diabetes.

Your cart is currently empty.

Return to shop

SKU N/A Categories , , , ,
0